3 Pharmaceutical Formulations Company, Crop Protection Chemicals Company and Laminated Tubes Packaging Maker Stocks With a Strong Future Roadmap: Alembic Pharmaceuticals, Sharda Cropchem and EPL

Generic pharma, crop care and tube stocks give investors a way to track businesses that sit close to everyday demand in India. Alembic Pharmaceuticals, Sharda Cropchem and EPL cover a pharmaceutical formulations company, a crop protection chemicals company and a laminated tubes packaging maker.

This list covers three generic pharma, crop care and tube stocks with complete current figures: Alembic Pharmaceuticals, Sharda Cropchem and EPL. Every figure comes from the latest reported financials and the 10 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Generic Pharma, Crop Care and Tube Stocks?

Generic pharma, crop care and tube stocks are listed companies that develop and sell generic and specialty medicines, supply crop protection chemicals to farmers across many countries, and make laminated tubes and packaging for oral care, beauty and pharma brands. Their earnings depend on prescription demand, farm seasons and packaged goods volumes.

Generic Pharma, Crop Care and Tube Stocks at a Glance

On valuation, all three trade at a P/E below their industry P/E, which means the market is pricing them at a lower multiple than their peer group. Readers comparing generic pharma, crop care and tube stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain. With the Q2 FY27 results season close, investors in generic pharma, crop care and tube stocks can use the coming numbers to test whether growth is holding.

Why Do Generic Pharma, Crop Care and Tube Stocks Have a Strong Roadmap in India?

Generic pharma, crop care and tube stocks have a strong roadmap in India because steady global demand for medicines, wider use of crop protection and growing sales of branded personal care products keep widening the market for these companies.

• Pharma. Doctors prescribe generic and specialty medicines.
• Crop chemicals. Farmers protect crops across many countries.
• Packaging. Brands need safe and attractive tubes.

Why Alembic Pharmaceuticals Features Among These Generic Pharma, Crop Care and Tube Stocks

Among the generic pharma, crop care and tube stocks on this list, Alembic Pharmaceuticals is a Vadodara-based drug maker that sells generic formulations in the United States, branded medicines in India and active ingredients to other manufacturers.

The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7.

Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore.

Roadmap: The company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

What to watch: Follow new approvals in the United States, the pace of complex generic launches and domestic growth.

Why Sharda Cropchem Features Among These Generic Pharma, Crop Care and Tube Stocks

Among the medicine maker, crop protection and packaging shares on this list, Sharda Cropchem is a Mumbai-based agrochemical company that registers and sells crop protection products in Europe, Latin America, North America and other regions, along with non-agro chemicals.

Revenue rose from Rs 3,609 crore in FY22 to Rs 5,410 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 349 crore in FY22 to Rs 681 crore in FY26, which works out to a compound annual growth rate of 18.2%.

In the June 2026 quarter, revenue grew 8.9% year on year to Rs 1,108 crore. The company has a return on equity of 21.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 6,314 crore. The stock trades at a P/E of 10.1, below the industry P/E of 23.3.

Roadmap: The company holds a large portfolio of product registrations in regulated markets, which is a barrier for new entrants. It sells through a lean, asset-light model, and carries no debt.

What to watch: Monitor the revenue mix of new registrations and the trend in global agrochemical prices.

Why EPL Features Among These Generic Pharma, Crop Care and Tube Stocks

Among the three companies on this list, EPL is among the world's largest makers of laminated plastic tubes used for toothpaste, beauty, personal care and pharmaceutical products. It operates plants across Asia, Europe, the Americas and Africa.

In the June 2026 quarter, revenue grew 24.7% year on year to Rs 1,392 crore. Revenue rose from Rs 3,445 crore in FY22 to Rs 4,806 crore in FY26, a compound annual growth rate of 8.7%.

Net profit grew from Rs 221 crore in FY22 to Rs 394 crore in FY26, which works out to a compound annual growth rate of 15.5%. The company has a return on equity of 13.6%, a debt to equity ratio of 0.34 and a market capitalisation of Rs 7,244 crore. The stock trades at a P/E of 18.4, below the industry P/E of 21.7.

Roadmap: The company is growing sustainable tube formats such as recyclable tubes, which global brands increasingly prefer. A wide plant network lets it serve large customers in many regions.

What to watch: Track the share of sustainable tubes in sales and volume growth in beauty and personal care.

Alembic Pharmaceuticals vs Sharda Cropchem vs EPL on Key Financials

The table below sets the three generic pharma, crop care and tube stocks side by side on revenue, profit and margin, using reported figures.

Sharda Cropchem posts the highest return on equity in this group at 21.7%. Alembic Pharmaceuticals has the largest FY26 revenue at Rs 7,399 crore, and Sharda Cropchem shows the fastest revenue growth with a 10.7% compound annual rate. A useful habit with generic pharma, crop care and tube stocks is to check each new quarterly result against the capacity plans the company described earlier.

The June 2026 quarter, the latest reported, gives a fresh read on momentum:

Key Risks to Check Before Investing in Generic Pharma, Crop Care and Tube Stocks

Every theme carries risks that deserve a check before any decision. For these generic pharma, crop care and tube stocks, the main points are: Long-term medicine maker, crop protection and packaging shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

• Pricing pressure. Generic prices can change by market.
• Season and monsoon. Crop protection sales follow rain and pest cycles.
• Raw material costs. Ingredient and packaging prices can move margins.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter generic pharma, crop care and tube stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Generic Pharma, Crop Care and Tube Stocks

Generic pharma, crop care and tube stocks work best when investors track growth, valuation and return on equity side by side. Alembic Pharmaceuticals, Sharda Cropchem and EPL each have a clear plan to grow. Based on the 10 November 2026 close, Alembic Pharmaceuticals trades at Rs 1,017.3, Sharda Cropchem at Rs 690.5 and EPL at Rs 224.41. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these generic pharma, crop care and tube stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track generic pharma, crop care and tube stocks, set price alerts and get research-backed stock ideas.

What are generic pharma, crop care and tube stocks?

Ans. Generic pharma, crop care and tube stocks are listed companies that develop and sell generic and specialty medicines, supply crop protection chemicals to farmers across many countries, and make laminated tubes and packaging for oral care, beauty and pharma brands. Their earnings depend on prescription demand, farm seasons and packaged goods volumes. This list looks at three of them, Alembic Pharmaceuticals, Sharda Cropchem and EPL, using reported FY22 to FY26 financials and the 10 November 2026 closing prices.

Which generic pharma, crop care and tube stocks are covered in this list?

Ans. This list covers Alembic Pharmaceuticals, Sharda Cropchem and EPL. Based on the 10 November 2026 close, Alembic Pharmaceuticals traded at Rs 1,017.3, Sharda Cropchem at Rs 690.5 and EPL at Rs 224.41. Their return on equity ranges from 11.9% to 21.7%, and their revenue compound annual growth from FY22 to FY26 ranges from 8.4% to 10.7%.

Why do generic pharma, crop care and tube stocks have a strong future roadmap in India?

Ans. Generic pharma, crop care and tube stocks have a strong roadmap in India because steady global demand for medicines, wider use of crop protection and growing sales of branded personal care products keep widening the market for these companies. The main drivers are as follows. Pharma. Doctors prescribe generic and specialty medicines. Crop chemicals. Farmers protect crops across many countries. Packaging. Brands need safe and attractive tubes. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Alembic Pharmaceuticals performed financially?

Ans. Revenue rose from Rs 5,356 crore in FY22 to Rs 7,399 crore in FY26, a compound annual growth rate of 8.4%. Net profit grew from Rs 521 crore in FY22 to Rs 671 crore in FY26, which works out to a compound annual growth rate of 6.5%. In the June 2026 quarter, revenue grew 26.1% year on year to Rs 2,165 crore, while net profit rose 12.2% to Rs 172 crore. The company has a return on equity of 11.9%, a debt to equity ratio of 0.25 and a market capitalisation of Rs 14,914 crore. The stock trades at a P/E of 21.6, below the industry P/E of 35.7. Looking ahead, the company is moving into complex generics such as injectables and ophthalmic products, which tend to face less competition. Steady growth in the India branded business adds stability.

How has Sharda Cropchem performed financially?

Ans. Revenue rose from Rs 3,609 crore in FY22 to Rs 5,410 crore in FY26, a compound annual growth rate of 10.7%. Net profit grew from Rs 349 crore in FY22 to Rs 681 crore in FY26, which works out to a compound annual growth rate of 18.2%. In the June 2026 quarter, revenue grew 8.9% year on year to Rs 1,108 crore. The company has a return on equity of 21.7%, a debt to equity ratio of 0.00 and a market capitalisation of Rs 6,314 crore. The stock trades at a P/E of 10.1, below the industry P/E of 23.3. Looking ahead, the company holds a large portfolio of product registrations in regulated markets, which is a barrier for new entrants. It sells through a lean, asset-light model, and carries no debt.

How has EPL performed financially?

Ans. Revenue rose from Rs 3,445 crore in FY22 to Rs 4,806 crore in FY26, a compound annual growth rate of 8.7%. Net profit grew from Rs 221 crore in FY22 to Rs 394 crore in FY26, which works out to a compound annual growth rate of 15.5%. In the June 2026 quarter, revenue grew 24.7% year on year to Rs 1,392 crore. The company has a return on equity of 13.6%, a debt to equity ratio of 0.34 and a market capitalisation of Rs 7,244 crore. The stock trades at a P/E of 18.4, below the industry P/E of 21.7. Looking ahead, the company is growing sustainable tube formats such as recyclable tubes, which global brands increasingly prefer. A wide plant network lets it serve large customers in many regions.

What risks should investors check before buying generic pharma, crop care and tube stocks?

Ans. Investors should check a few risks before buying generic pharma, crop care and tube stocks. Pricing pressure. Generic prices can change by market. Season and monsoon. Crop protection sales follow rain and pest cycles. Raw material costs. Ingredient and packaging prices can move margins. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of generic pharma, crop care and tube stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 10 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.